— Know what they know.
Not Investment Advice
OABIW (NASDAQ) is a cross-listing of OABI (NASDAQ). Showing primary listing data.

OABI

OmniAb, Inc.
1W: -2.2% 1M: +2.3% 3M: -15.1% YTD: -6.9% 1Y: -31.1% 3Y: -52.5%
$1.75
-0.09 (-4.89%)
After Hours: $1.83 (+0.08, +4.86%)
NASDAQ · Healthcare · Biotechnology · $199.2M · Alpha Radar Buy · Power 58
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$199.2M
52W Range1.22-2.57
Volume753,378
Avg Volume344,391
Beta0.85
Dividend
Analyst Ratings
9 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOMatthew W. Foehr
Employees114
SectorHealthcare
IndustryBiotechnology
IPO Date2021-09-30
Websiteomniab.com
5980 Horton Street
EmeryVille, CA 94608
US
510 250 7800
About OmniAb, Inc.

OmniAb, Inc., a biotechnology company, provides therapeutic antibody discovery technologies in the United States. The company's discovery platform provides industry partners access to the diverse antibody repertoires and screening technologies to enable discovery of next-generation therapeutics. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur that features unique structural attributes of cow antibodies for complex targets. The company was founded in 2012 and is headquartered in Emeryville, California.

Recent Insider Trades

NameTypeSharesPriceDate
Berkman Charles S M-Exempt 18,750 2026-02-18
Berkman Charles S S-Sale 9,673 $1.71 2026-02-18
Berkman Charles S M-Exempt 18,750 2026-02-18
Berkman Charles S A-Award 60,000 2026-02-18
Berkman Charles S A-Award 600,000 $1.71 2026-02-18

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms